ReportGem ReportGem

U.S. COMPANY FILING

Moderna, Inc. — Form 10-K filed 2026-02-20

Filed: 2026-02-20Company: Moderna, Inc.Ticker: MRNAExchange: NasdaqForm: 10-KReport period: 2025-12-31SEC accession: 0001682852-26-000033Event: earningsMateriality: 85

Filing text preview

Moderna's 2025 revenue was $1.9 billion, down from $3.2 billion in 2024, with a net loss of $2.77 billion and EPS of -$7.26. Cash and investments totaled $8.1 billion, including a $600 million term loan drawdown. mNEXSPIKE launched in Q3 2025 and became the leading U.S. retail product. Positive five-year data for mRNA-4157 with Merck was announced. The company expects 2026 revenue growth and targets cash breakeven.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-02-20US Treasury to At Least Double Debt Buybacks; Stock Futures Climb2026-08-20Merck and Moderna's Melanoma Vaccine Trial Positive, Vaccine Themed ETFs Surge2026-08-20S&P 500 and Nasdaq Edge Higher, Led by Moderna and Merck2026-08-20US Stock Index Futures Climb As Yields Cool Off Amid Treasury Support2026-08-20Wall St Rises as Yields Ease, Moderna Lifts Healthcare Stocks2026-08-20Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data, Personalized Cancer Vaccine Meets Goal2026-08-2010-Q2026-07-31 · 10-Q